Objective: To examine whether having a prescribed ACEi was associated with increased dietary sodium density.
Methods: This was a secondary analysis of baseline data from HF patients in an observational longitudinal study. Dietary sodium intake measured from 4-day food diaries was analyzed with NDS-R software (NRCC, Minneapolis, MN). To control for differences in dietary sodium due to differences in amount of food consumed, dietary sodium density was calculated as 4-day averaged daily sodium intake divided by averaged kilocalories (kcal) consumed. Prescribed medications were ascertained through medical chart review. Patients were categorized into 2 groups: those prescribed and those not prescribed ACEi. We used t-tests to compare sodium intake between ACEi groups. Linear regression was conducted to determine whether prescribed ACEi independently predicted sodium density controlling for age, gender, New York Heart Association (NYHA) Class, and prescribed diuretics and beta blockers.
Results: There were 262 HF patients (age 61 ± 12, 68% male, 44% NYHA Class III/IV); 76% were prescribed a diuretic, 89% a beta blocker, and 68% an ACEi. Patients prescribed ACEi consumed 13% more sodium per kcal than those not prescribed ACEi (1.8 mg Na/kcal vs. 1.6 mg Na/kcal, p = .001). Prescribed ACEi independently predicted dietary sodium density (beta=.207, p=.002). No confounding factors predicted density.
Conclusions: The results support the hypothesis that patients on an ACEi have higher sodium intake. Assessing medication regimen is important for planning interventions to enhance HF patients’ adherence to dietary sodium restriction. Research is needed to explore HF patients’ salt taste perception to better understand associations between medication regimen and sodium intake.
See more of: Invited Posters